INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

11119	Companies
244817	Keywords
172888	Articles
132001	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 04/15/2025 at 22:00, 1 year 5 months ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inventiva files its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F with the AMF and SEC. Documents accessible on Inventiva's website and regulatory authorities' sites

2024 Form 20-F Registration Document Clinical-Stage Biopharmaceutical Inventiva
PRESS RELEASE

published on 04/15/2025 at 22:00, 1 year 5 months ago

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F »)
Inventiva dépose son Document d’Enregistrement Universel 2024 et son Rapport Annuel 2024 (Form 20-F) auprès de l’AMF et de la SEC. Les documents sont disponibles sur les sites internet respectifs

AMF SEC Inventiva Rapport Annuel 2024 Document D'Enregistrement Universel 2024
BRIEF

published on 03/26/2025 at 21:05, 1 year 6 months ago

Inventiva dévoile ses résultats financiers 2024 et ses projets stratégiques

Réorganisation Stratégique Résultats Financiers 2024 Recherche & Développement Lanifibranor Financement Structuré
BRIEF

published on 03/26/2025 at 21:05, 1 year 6 months ago

Inventiva unveils its 2024 financial results and strategic projects

Strategic Reorganization 2024 Financial Results Research & Development Lanifibranor Structured Financing
PRESS RELEASE

published on 03/26/2025 at 21:00, 1 year 6 months ago

Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité avec chiffre d'affaires de 9,2 millions d'euros, trésorerie à 96,6 millions d'euros et levée de 116 millions d'euros

Chiffre D'affaires Résultats Financiers Financement Trésorerie Inventiva
PRESS RELEASE

published on 03/26/2025 at 21:00, 1 year 6 months ago

Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented

Revenues Financial Results Inventiva Cash Equivalents NATiV3 Phase 3 Trial
BRIEF

published on 03/19/2025 at 21:05, 1 year 6 months ago

Inventiva Announces 2024 Full-Year Financial Results Schedule

Financial Results Webcast Inventiva Lanifibranor MASH Treatment
BRIEF

published on 03/19/2025 at 21:05, 1 year 6 months ago

Inventiva annonce le calendrier des résultats financiers annuels 2024

Résultats Financiers Webcast Inventiva Lanifibranor Traitement MASH
PRESS RELEASE

published on 03/19/2025 at 21:00, 1 year 6 months ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Inventiva schedules 2024 Full-Year Financial Results presentation on March 27, 2025. Webcast available. Company focused on small molecule therapies for MASH

Presentation 2024 Financial Results Inventiva MASH Small Molecule Therapies
PRESS RELEASE

published on 03/19/2025 at 21:00, 1 year 6 months ago

Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2024. La présentation aura lieu le 27 mars 2025 avec une conférence téléphonique le 30 mars 2025

Presentation Conférence Téléphonique Thérapies Orales Résultats Financiers 2024 Inventiva

Accesswire

Published on 10/03/2026 at 02:35, 1 day 18 hours ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 2 days 2 hours ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 2 days 6 hours ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 2 days 7 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 2 days 7 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/04/2026 at 06:05, 14 hours 32 minutes ago

Blokees Debuts 90+ New Products at Wonder Festival Shanghai 2026
Published on 10/04/2026 at 05:15, 15 hours 22 minutes ago

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
Published on 10/03/2026 at 15:45, 1 day 4 hours ago

Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 1 day 20 hours ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 2 days ago

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding

Les Echos

Published on 10/02/2026 at 17:45, 2 days 2 hours ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:45, 2 days 2 hours ago

Informations relatives au nombre total de droits de vote et d’actions 2026 09 30
Published on 10/02/2026 at 17:35, 2 days 3 hours ago

Peugeot Invest - Déclaration du nombre d'actions et de droits de vote
Published on 10/02/2026 at 17:30, 2 days 3 hours ago

Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/02/2026 at 17:30, 2 days 3 hours ago

Aéroports de Paris SA - Calendrier financier 2027

View all LES ECHOS COMFI WIRE